文献速递产科母胎医学

短宫颈女性维持性保胎治疗中使用孕激素:一项随机对照试验

Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2017-01-01

在五所大学医院开展的随机对照试验中,单胎妊娠22 0/7至31 6/7周、首次早产发作停止后出院时宫颈长度≤25 mm的257名女性被随机分配至阴道孕酮组(86例)、肌注17α-羟孕酮己酸酯组(87例)或观察组(81例)。计划中期分析(n=254)时因无效而终止试验,孕激素未能降低37周前早产率。

要点

  • 阴道孕酮组37周前早产率为39%,17α-羟孕酮己酸酯组为23%,观察组为22%。
  • 17α-羟孕酮己酸酯组与观察组比较P=.949,阴道孕酮组与观察组比较P=.027。
  • 孕激素用于短宫颈女性维持性保胎未降低早产率。

核心结论

  • 孕激素用于短宫颈女性维持性保胎未降低早产率。

研究设计与样本

  • 在五所大学医院开展的随机对照试验,纳入单胎妊娠22 0/7至31 6/7周、早产发作停止且出院时宫颈长度≤25 mm的女性,排除既往早产史者。
  • 257名合格女性被随机分配至阴道孕酮组(n=86)、肌注17α-羟孕酮己酸酯组(n=87)或观察组(n=81)。
  • 19例(8%)因退出或信息缺失被排除分析,最终235名女性纳入分析。
  • 计划每组样本量160例(n=480),基于对照组早产风险30%、孕激素降至15%的假设,P<.025为统计学显著。
  • 计划中期分析(n=254)时因无效而终止试验。

主要发现

  • 37周前早产率:17α-羟孕酮己酸酯组23%,阴道孕酮组39%,观察组22%。
  • 17α-羟孕酮己酸酯组与观察组比较P=.949,阴道孕酮组与观察组比较P=.027。
  • 各组人口学特征相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 计划中期分析(n=254)时因无效而终止试验。
  • 19例(8%)因退出或信息缺失被排除分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy of progestogens for maintenance tocolysis in women undelivered after their first preterm labor episode. METHODS: Women with singleton pregnancies between 22 0/7 and 31 6/7 weeks of gestation with arrested preterm labor and a cervical length 25 mm or less at hospital discharge were eligible. Patients with a previous preterm birth were excluded. In a randomized controlled trial conducted in five university hospitals, women were randomized to receive vaginal progesterone (200 mg per day) or intramuscular 17α-hydroxyprogesterone caproate (341 mg per week) or to an observation groups (control group). The primary outcome was the proportion of women with preterm birth at less than 37 weeks of gestation. A sample size of 160 per group (n=480) was planned to compare vaginal progesterone and 17α-hydroxyprogesterone caproate groups with those in the control group. The sample size estimation was based on the hypothesis that the risk of experiencing preterm birth in the control group would be 30% and that 17α-hydroxyprogesterone caproate or progesterone would decrease this risk to 15%. A P value of <.025 was defined as statistically significant. At planned interim analysis (n=254), the trial was stopped for futility. RESULTS: Between July 2010 and June 2015, 257 women were eligible and 254 were subsequently randomly assigned to vaginal progesterone (n=86), 17α-hydroxyprogesterone caproate (n=87), or observation (n=81). Nineteen (8%) were excluded from the analysis because they either dropped out or information was missing, leaving 235 women available for analysis. Demographic characteristics were similar across groups. The preterm birth rate did not differ significantly between groups: 23% in the 17α-hydroxyprogesterone caproate group, 39% in the vaginal progesterone group, and 22% in the women in the control group (P=.949 for 17α-hydroxyprogesterone caproate compared with the women in the control group and P=.027 for vaginal progesterone compared with women in the control group). CONCLUSION: The use of progestogens for maintenance tocolysis in women with a short cervix did not reduce the rate of preterm birth. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01178788.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Facchinetti F, Vergani P, Di Tommaso M, et al. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial. Obstet Gynecol. 2017. PMID: 28594783. doi:10.1097/AOG.0000000000002065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。